EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Optimizing hyperkalemia management in CKD: real-world nephrologist strategies and impact on patient outcomes

María Marques iD, Paula López-Sánchez iD, Enrique Morales iD, M Auxiliadora Bajo iD, Antolina Rodriguez, Milagros Fernández Lucas, Vicente Paraiso, Laura Bucalo, Yolanda Hernandez, José C De La Flor, Maite Padrón, Hanane Bouarich und 4 weitere

Journal of Nephrology · 30.10.2026 · 39 (8) · 1607-1615

DOI: 10.1093/joneph/aajag149 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Nephrology, online erschienen am 14.08.2026. Verfasst von María Marques und 15 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, HU Puerta de Hierro-Majadahonda, Majadahonda, Spain. Hauptthemen laut MEDLINE: Hyperkalemia, Mineralocorticoid Receptor Antagonists, Potassium, Renal Insufficiency, Chronic. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III, Unión Europea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hyperkalemia is a common complication in chronic kidney disease (CKD), requiring management to maintain cardiovascular benefits of renin–angiotensin–aldosterone system and mineralocorticoid receptors (RAASi/MRA) therapy. This study evaluated hyperkalemia management and recurrence in CKD patients.

Methods

A prospective, multicenter observational study was conducted across 15 hospitals, enrolling 429 patients with serum potassium > 5.5 mmol/L. Patients were managed per usual practice, and data on recurrence, RAASi/MRA changes, cardiovascular events, and renal function were collected over 2 years.

Results

Cohort (mean age 71.5 years, 71.3% male, 88.6% hypertension, 55.9% diabetes) presented with mild, moderate (19.1%), and severe (3.7%) hyperkalemia. Post-event, dietary modifications increased by 39.9%, bicarbonate use by 7.9%, resin use by 2.6%, patiromer use by 10.9%, and sodium zirconium cyclosilicate (SZC) use by 24.6%. Modifications on RAA Si/MRA therapy were as follows: angiotensin-converting enzyme inhibitors reduced in 12% and suspended in 6.8%; angiotensin II receptor blockers reduced in 5.49% and suspended in 7.32%; and MRA reduced in 12.73% and suspended in 21.82%. Recurrence occurred in 43.8%, with higher rates in patients with baseline estimated glomerular filtration rate <30 ml/min (49.1% vs 38.8%, P = 0.03). Recurrent hyperkalemia was associated with faster eGFR decline (−2.4 ml/min/year, P < 0.001). Kaplan–Meier analysis showed no differences in overall survival between patients with and without recurrence. The study found no significant difference between patiromer/SZC and resins in efficacy (recurrence rates).

Conclusion

Integrating potassium binders into CKD therapeutic strategies may improve hyperkalemia management and allow sustained RAASi/MRA use. Recurrence remains significant, impacting renal function, although causality is unclear. The mortality difference requires further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperkalemiaMineralocorticoid Receptor AntagonistsPotassiumRenal Insufficiency, ChronicAgedAged, 80 and overFemaleHumansMaleMiddle AgedAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBicarbonatesBiomarkersGlomerular Filtration RatePolymersProspective StudiesRecurrenceRenin-Angiotensin SystemRisk FactorsSilicatesTime FactorsTreatment Outcome

Stichwörter der Autor:innen

RAASichronic kidney diseasehyperkalemiapotassium binders

Substanzen

Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBicarbonatesBiomarkersMineralocorticoid Receptor AntagonistspatiromerPolymersPotassiumSilicatessodium zirconium cyclosilicate

Autor:innen und Institutionen

  • Nephrology Department, HU Puerta de Hierro-Majadahonda, Majadahonda, Spain.
  • Medicine Department, Facultad Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
  • Nephrology Department, HU Doce de Octubre, Madrid, Spain.
  • Nephrology Department, HU La Princesa, Madrid, Spain.
  • Nephrology Department, HU Clínico San Carlos, Madrid, Spain.
  • Nephrology Department, HU Ramón y Cajal, Madrid, Spain.

ORCID-Profile: María Marques, Paula López-Sánchez, Enrique Morales, M Auxiliadora Bajo, Fabio Procaccini, Coraima Nava Chavez

Förderung

  • Instituto de Salud Carlos III
  • Unión Europea

Zitieren

APA

Marques, M., López-Sánchez, P., Morales, E., Bajo, M. A., Rodriguez, A., Fernández Lucas, M., Paraiso, V., Bucalo, L., Hernandez, Y., De La Flor, J. C., Padrón, M., Bouarich, H., Procaccini, F., Nava Chavez, C., Herrero, J., & Tornero, F. (2026). Optimizing hyperkalemia management in CKD: real-world nephrologist strategies and impact on patient outcomes. Journal of Nephrology, 39(8), 1607-1615. https://doi.org/10.1093/joneph/aajag149

Vancouver

Marques M, López-Sánchez P, Morales E, Bajo MA, Rodriguez A, Fernández Lucas M, et al. Optimizing hyperkalemia management in CKD: real-world nephrologist strategies and impact on patient outcomes. Journal of Nephrology. 2026;39(8):1607-1615. doi:10.1093/joneph/aajag149

BibTeX
@article{Marques2026,
  author = {Marques, María and López-Sánchez, Paula and Morales, Enrique and Bajo, M Auxiliadora and Rodriguez, Antolina and Fernández Lucas, Milagros and Paraiso, Vicente and Bucalo, Laura and Hernandez, Yolanda and De La Flor, José C and Padrón, Maite and Bouarich, Hanane and Procaccini, Fabio and Nava Chavez, Coraima and Herrero, Jose and Tornero, Fernando},
  title = {Optimizing hyperkalemia management in CKD: real-world nephrologist strategies and impact on patient outcomes},
  journal = {Journal of Nephrology},
  year = {2026},
  volume = {39},
  number = {8},
  pages = {1607--1615},
  doi = {10.1093/joneph/aajag149}
}
Kostenlos starten →